Burrill Institutional Research initiated coverage on shares of Sangamo Biosciences (NASDAQ: SGMO) in a research note released on Tuesday morning. The firm issued an outperform rating and a $28.00 price target on the stock.
“We believe Sangamo’s innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren’t included in our calculation.,” the firm’s analyst wrote.
A number of other analysts have also recently weighed in on SGMO. Analysts at Piper Jaffray upgraded shares of Sangamo Biosciences from an underweight rating to an overweight rating in a research note to investors on Thursday, January 3rd. Analysts at Zacks downgraded shares of Sangamo Biosciences from an outperform rating to a neutral rating in a research note to investors on Tuesday, December 25th. They now have a $6.60 price target on the stock.
Shares of Sangamo Biosciences opened at 9.05 on Tuesday. Sangamo Biosciences has a 52 week low of $4.01 and a 52 week high of $10.05. The stock’s 50-day moving average is currently $8.55. The company’s market cap is $479.5 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
